EVIDENCE MATRIX / FIVE ENTRIES
Compare the Question Before the Compound
A side-by-side view of what each entry is, why it is studied, how mature its evidence is, and where inference must stop.
In plain English
These five entries are not alternatives for one shared purpose. They belong to different branches of biology and sit at different points on the evidence ladder. Semaglutide activates a metabolic hormone receptor and has large human outcome trials. BPC-157 is studied mainly in animal repair models. Ipamorelin triggers growth-hormone release but has limited human trials and no proven clinical indication. NAD+ is a cellular coenzyme, not a peptide; precursor studies often measure blood biomarkers. GHK-Cu is a copper-bound tripeptide studied mainly in skin, matrix, and hair contexts.
A useful comparison therefore starts with the research question, not with popularity. The next checks are model, outcome, evidence maturity, formulation, and regulatory category. A positive cell study cannot be compared directly with a cardiovascular outcome trial. A topical cosmetic cannot be treated as evidence for injection. A product available online is not thereby approved or clinically validated. The matrix below preserves those distinctions and shows why a single label—research peptides—can obscure more than it explains.
The evidence matrix
| Entry | What it is | Main mechanism | Strongest selected evidence | Evidence boundary |
|---|---|---|---|---|
| Semaglutide | Long-acting GLP-1 analogue | GLP-1 receptor agonism; glucose-dependent insulin signalling and central appetite regulation | Large human weight, cardiovascular, and kidney outcome trials [2][3][4] | Benefits and harms remain population-, indication-, and product-specific [5][7] |
| BPC-157 | Synthetic gastric pentadecapeptide | VEGFR2-linked angiogenesis and cytoprotective pathways | Animal and cell repair studies; tiny human safety pilot [8][11][12] | No rigorous large-scale human efficacy base [9] |
| Ipamorelin | Selective ghrelin-receptor agonist peptide | Pituitary growth-hormone release through GHS-R1a | Acute human pharmacology and one controlled postoperative trial [15][16] | Controlled trial missed its primary endpoint; long-term safety unknown [15] |
| NAD+ | Endogenous redox coenzyme, not a peptide | Electron transfer and substrate roles for sirtuins, PARPs, and CD38 | Human precursor trials show blood NAD+ changes and selected metabolic signals [19][20][22] | Biomarker change does not establish longevity or disease prevention [18] |
| GHK-Cu | Copper-binding tripeptide | Copper carriage, matrix signalling, and gene-expression effects | Small topical and hair studies plus laboratory and ex vivo work [23][25][27] | Delivery is difficult; systemic use lacks a human evidence base [23] |
Mechanism is a map, not a verdict
Mechanisms explain the route from molecule to possible effect. Semaglutide's GLP-1 receptor activity connects plausibly to appetite and glucose regulation, and dedicated trials then demonstrate measured outcomes [2][3][4]. BPC-157's VEGFR2 activity connects plausibly to vascular repair, but human outcome confirmation is missing [9][11]. Ipamorelin's ghrelin-receptor activity produces a measurable growth-hormone pulse, while the intended postoperative benefit was not demonstrated [15][16].
NAD+ and GHK-Cu show two other limits. Raising a blood NAD+ marker does not establish a tissue-level longevity effect [18][22]. Changing gene-expression pathways with GHK does not prove that a topical product reaches the target tissue or produces whole-body rejuvenation [23][24]. The closer a claim moves toward a meaningful human benefit, the more demanding the evidence must become. Receptor binding, cell signalling, animal models, pilot studies, randomised surrogate-endpoint trials, and major outcome trials belong on different rungs.
Evidence maturity changes the language
Semaglutide supports the most confident verbs in this collection because randomised human studies measured clinical events and substantial weight outcomes [2][3][4]. Even there, claims must remain tied to the studied populations and adverse-effect record [5][7]. For BPC-157, the accurate verbs are suggests, was associated with, and was observed in an animal model. For ipamorelin, acute hormone release is established, but broad claims about physique, sleep, or ageing remain unsupported by controlled outcomes [15][16].
For NAD+ precursors, raised blood NAD+ is more defensible than reversed ageing [18][19][22]. For GHK-Cu, altered expression or produced a topical signal is more defensible than regenerated the body [23][24][26]. This is not timid writing. It is a direct reflection of study design. Precision prevents weak evidence from borrowing the authority of strong evidence simply because both appear on the same site.
Regulation, access, and research participation
Regulatory status is not a scientific effect size. A regulator assesses a defined product, indication, manufacturing standard, and evidence package. A clinical trial grants access through a protocol, eligibility criteria, ethics oversight, and accountable investigators. A sporting body applies a separate prohibited-substances framework. A laboratory supplier label describes intended supply context, not proof that personal use is a legitimate experiment.
The composed corpus identifies semaglutide as an approved prescription medicine for specified uses in its source jurisdiction, while BPC-157 and ipamorelin are not approved medicines. GHK-Cu has a topical cosmetic context but no approved systemic use in the corpus. NAD+ precursors, supplements, and compounded infusion products occupy still other categories. None of those statements should be converted automatically into a current Australian determination. Australian status must be checked against the applicable official record for the exact product and use.
This approach also guards against a common substitution: treating access as validation. Ease of purchase, clinic promotion, or community familiarity supplies no missing trial data.
The most important caution for each
For semaglutide, substantial benefits coexist with gastrointestinal, biliary, and retinopathy cautions that require clinical context [5][7]. For BPC-157, the dominant caution is the absence of an adequate human evidence base, compounded by unverified supply [8][9]. For ipamorelin, the defining risk is long-term uncertainty across the growth-hormone axis, metabolism, fluid balance, and cardiovascular systems; the class-level rat signal came from another agonist and must be labelled accordingly [14].
For NAD+, the key caution is overinterpreting target engagement: blood NAD+ elevation is not proof of longevity, while formulation and route introduce separate quality questions [18][22]. For GHK-Cu, the central caution is route and formulation: topical evidence and cosmetic use cannot validate systemic exposure, and poor skin permeability complicates product-to-product inference [23][27].
Across all five, the most reliable rule is to ask exactly what was tested, in whom or what model, against which comparator, for how long, and with which outcome. When any part of that sentence is missing, confidence should fall rather than imagination filling the gap.